Cited by 214Chemokine receptors and signalingChronic Obstructive Pulmonary Disease (COPD) ResearchAsthma and respiratory diseases

CXCR2 antagonists for the treatment of pulmonary disease

Chapman, R.W., Phillips, J.E., Hipkin, R.W., Curran, A.K., Lundell, D., Fine, J.S.·2009·Pharmacology & Therapeutics

Abstract

Chemokines have long been implicated in the initiation and amplification of inflammatory responses by virtue of their role in leukocyte chemotaxis. The expression of one of the receptors for these chemokines, CXCR2, on a variety of cell types and tissues suggests that these receptors may have a broad functional role under both constitutive conditions and in the pathophysiology of a number of acute and chronic diseases. With the development of several pharmacological, immunological and genetic tools to study CXCR2 function, an important role for this CXC chemokine receptor subtype has been identified in chronic obstructive pulmonary disease (COPD), asthma and fibrotic pulmonary disorders. Interference with CXCR2 receptor function has demonstrated different effects in the lungs including inhibition of pulmonary damage induced by neutrophils (PMNs), antigen or irritant-induced goblet cell hyperplasia and angiogenesis/collagen deposition caused by lung injury. Many of these features are common to inflammatory and fibrotic disorders of the lung. Clinical trials evaluating small molecule CXCR2 antagonists in COPD, asthma and cystic fibrosis are currently underway. These studies hold considerable promise for identifying novel and efficacious treatments of pulmonary disorders.

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2008.10.005

Cites

205 of 205 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Chapman, R. W., Phillips, J. E., Hipkin, R. W., Curran, A. K., Lundell, D., & Fine, J. S.
Corresponding author
Chapman, R.W.
Venue
Pharmacology & Therapeutics
Publisher
Elsevier BV
Published
2009-01
Volume
121
Issue
1
Pages
55-68
ISSN
0163-7258 (ISSN-L)
OpenAlex
W1988019968
Cited by
214
References
205
Citations by year
2026: 1 · 2025: 8 · 2024: 3 · 2023: 12 · 2022: 2 · 2021: 10 · 2020: 12 · 2019: 3 · 2018: 15 · 2017: 11 · 2016: 10 · 2015: 21 · 2014: 23 · 2013: 17 · 2012: 23
FWCI
1.34
Type
journal article
Language
en
Open access
closed
Locations
  • Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
Keywords
CXCR2 antagonist, chemokines, chronic obstructive pulmonary disease, asthma, pulmonary fibrosis, cystic fibrosis, neutrophil recruitment, goblet cell hyperplasia, lung injury, angiogenesis, collagen deposition, small molecule antagonists, clinical trials
MeSH terms
Animals, Chemotaxis, Leukocyte, Humans, Lung Diseases, Chemokines, CXC, Receptors, Interleukin-8B, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review